Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch
Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.
Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch Read More »
